Susan Guy and colleagues recently published a research paper, “Caution in Using the Activated Partial Thromboplastin Time to Monitor Argatroban in COVID-19 and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT),” in Clinical and Applied Thombosis/Hemostasis. Here we summarize their work. Argatroban is approved for the treatment of patients with heparin-induced thrombocytopenia (HIT), Vaccine-induced Immune Thrombocytopenia (VITT),…